Skip to main content
SpringerLink
Log in

Injectable Contraceptives

  • Chapter
Fertility Control — Update and Trends

Abstract

An estimated 16 million women throughout the world are currently relying on injectable steroids for contraception. The choice of injectable methods includes products effective for 3 months, 2 months, or 1 month (Table 1). Although little known in Europe, these methods represent the third most prevalent form of reversible contraception worldwide. Trend estimates suggest that this number is rising, due to the reassuring World Health Organization (WHO) data regarding cancer risk, and the recent approval of the 3-monthly injectable depo medroxy-progesterone acetate (DMPA, or Depo-Provera) by the United States Federal Drug Administration (USFDA).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • d’Arcangues C, Odlind V, Fraser I (1992) Dysfunctional uterine bleeding induced by exogenous hormones. In: N.J. Alexander, C. d’Arcangues (eds) Steroid hormones and uterine bleeding. Washington,AAAS Press, pp 81–105

    Google Scholar 

  • Aedo AR, Landgren BM, Johannisson E et al. (1985) Pharmacokinetic and pharmacodynamic investi gations with monthly injectable contraceptive preparation. Contraception 31: 453–469

    Article  PubMed  CAS  Google Scholar 

  • Allen S, Lindan C, Serufilira A et al. (1991) Human immunodeficiency virus infection in urban Rwan-da. JAMA 266: 1657–63

    Article  CAS  Google Scholar 

  • Amatayakul K, Sivassomboon B, Singkamani R (1980) Effects of medroxyprogesterone acetate on se-rum lipids, protein, glucose tolerance and liver function in Thai women. Contraception 21: 283–298

    Article  PubMed  CAS  Google Scholar 

  • Ashman JAM (1990) Monthly injectable contraceptives and breast cancer (Master of Science thesis). University of Washington, WA, USA

    Google Scholar 

  • Bahamondes L, Lavin P, Ojeda G et al. (1997) Return of fertility after discontinuation of the one-amonth injectable contraceptive cyclofem. Contraception 55: 307–310

    Article  PubMed  CAS  Google Scholar 

  • Bledsoe CH, Hill AG, D’Alessandro P et al. (1994) Forthcoming. local cultural interpretations of western contraceptive technologies in rural Gambia. Population and Development Review, March

    Google Scholar 

  • Cookson KM (1994) The parenteral toxicity of Cyclofem. Contraception 49: 335–345

    Article  PubMed  Google Scholar 

  • Coutinho E M, Spinola P, Barbosa I et al. (1997) Multicenter, double-blind, comparative clinical study on the efficacy and acceptability of a monthly injectable contraceptive combination of 150 mg dihydroxyprogesterone acetophenide and 10 mg estradiol enanthate compared to a monthly injectable contraceptive combination of 90 mg dihydroxyprogesterone acetophenide and 6 mg estradiol enanthate. Contraception 1997; 55: 175–181

    Article  Google Scholar 

  • Crabbé P, Archer S, Benagiano G, Diczfalusy E, Djerassi C, Fried J, Higuchi T (1983) Long-acting contraceptive agents: design of the WHO Chemical Synthesis Programme. Steroids 41: 243–253

    Article  PubMed  Google Scholar 

  • Croxatto HB, Diaz S, Peralta O et al. (1983) Fertility regulation in nursing women: IV. long-term influence of a low-dose combined oral contraceptive initiated at day 30 postpartum upon lactation and infant growth. Contraception 27: 13–25

    Article  PubMed  CAS  Google Scholar 

  • Cundy, T et al. (1991) Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ 303: 13–16

    CAS  Google Scholar 

  • Cundy T, Cornish, J, Evans MC, Roberts H, Reid, IR (1994) Recovery of bone density in women who stop using medroxyprogesterone acetate. BMJ 308: 247–248

    CAS  Google Scholar 

  • Cushman LF, Kalmuss D, Davidson AR et al. (1996) Beliefs about Depo-Provera among three groups of contraceptors. Adv Contracept 12: 43–52

    Article  PubMed  CAS  Google Scholar 

  • Diaz S, Peralta O, Juez G et al. (1983) Fertility regulation in nursing women: III. short-term influence of a low-dose combined oral contraceptive upon lactation and infant growth. Contraception 27: 1–11

    Google Scholar 

  • Egyptian Fertility Care Society (1993) A comparative clinical trial of two once-a-month injectable contraceptives ( Cyclofem and Mesigyna ). Final report (unpublished )

    Google Scholar 

  • Fotherby K, Benagiano G, Toppoyada HK et al. (1982) A preliminary pharmacological trial of the monthly injectable contraceptive, Cycloprovera. Contraception 25: 261–272

    Google Scholar 

  • Fotherby K, Saxena BN, Shrimanker K et al. (1980) A preliminary pharmacokinetic and pharmacodynamic evaluation of depot-medroxyprogesterone acetate and norethisterone oenanthate. Fertil Steril 34: 131–139

    PubMed  CAS  Google Scholar 

  • Fraser IS (1983) A survey of different approaches to management of menstrual disturbances in women using injectable contraceptives. Contraception 28: 385–397

    Article  PubMed  CAS  Google Scholar 

  • Fraser IS (1994) Vaginal bleeding patterns in women using once-a-month injectable contraceptives. Contraception 49: 399–420

    Article  PubMed  CAS  Google Scholar 

  • Fraser IS, Dennerstein GJ (1994) Depo-Provera use in an Australian metropolitan practice. Med J Aust 160: 553–556

    PubMed  CAS  Google Scholar 

  • Fraser IS, Diczfalusy E (1980) A perspective of steroidal contraception and abnormal bleeding: What are the prospects for improvement? In: Diczfalusy E, Fraser IS, Webb FTG (eds) Endometrial bleeding and steroidal contraception. Pitman Press Ltd, Bath, England, pp 384–413

    Google Scholar 

  • Garza-Flores J, Cardenas S, Rodriguez V, Cravioto MC, Diaz-Sanchez V, Perez-Palacios G (1985) Return to ovulation following the use of long-acting injectable contraceptives: a comparative study. Contraception 31: 361–366

    Article  PubMed  CAS  Google Scholar 

  • Garza-Flores J, Guo-wei S, Hall P (1994) Population and delivery systems: variability in pharmacokinetics of long-acting injectable contraceptives. In: Snow R, Hall P (eds) Steroid contraceptives and women’s response. Plenum Press, New York

    Google Scholar 

  • Garza-Flores J, Hall PE, Perez-Palacios G (1991) Long-acting hormonal contraceptives for women. J Steroid Biochem Mol Biol 40: 697–704

    Article  PubMed  CAS  Google Scholar 

  • Guzman-Gracia S, Snow R, Aitken I (1997) Preferences for contraceptive attributes: voices of women in ciudad Juarez, Mexico. Int Family Planning Perspect 23: 52–58

    Google Scholar 

  • Hall PE (1987) Long-acting injectable formulations. In: Diczfalusy E, Bydgeman M (eds) Fertility regulation today and tomorrow–Raven Press, New York pp 119–141

    Google Scholar 

  • Hall PE, WHO Task Force (1994) The introduction of cyclofem into national family planning programmes: experience from studies in Indonesia, Jamaica, Mexico, Thailand and Tunisia. Contraception 49: 489–507

    Google Scholar 

  • Hassan EO, El-Nahal N, El-Hussein M (1994) Acceptability of the once-a-month injectable contraceptive Cyclofem and Mesigyna in Egypt. Contraception 40 (5): 469–488

    Article  Google Scholar 

  • Herrero R, Brinton LA, Reeves WC et al. (1990) Injectable contraceptives and risk of invasive cervical cancer: evidence of an association. Int J Cancer 46: 5–7

    Article  PubMed  CAS  Google Scholar 

  • Howard G, Blair M, Fotherby K, Elder MG, Bye P (1985) Seven years clinical experience of the injectable contraceptive, norethisterone oenanthate. Br J Family Planning 11: 9–16

    Google Scholar 

  • ICMR Task Force on Hormonal Contraception (1986) Return of fertility following discontinuation of an injectable contraceptive–norethisterone oenanthate (net en) 200 mg dose. Contraception 34: 573–582

    Article  Google Scholar 

  • Jaffe B, Hralap S, Baras M et al. (1988) Long-term effects of MPA on human progeny: intellectual development. Contraception 37: 607–619

    Article  PubMed  CAS  Google Scholar 

  • Jaffe B, Shye D, Harlap S et al. (1989) Aggression, physical activity levels and sex role identity in teenagers exposed in utero to MPA. Contraception 40: 351–363

    Article  PubMed  CAS  Google Scholar 

  • Jaffe B, Shye D, Harlap S et al. (1990) Health, growth and sexual development of teenagers exposed in utero to medroxyprogesterone acetate. Paediatr Perinat Epidemiol 4: 184–195

    Article  PubMed  CAS  Google Scholar 

  • Johansson E, Odlind V (1987) The passage of exogenous hormones into breast milk–possible effects. Int J Gynaecol Obstet 25 [Supp1]: 111–114

    Article  PubMed  CAS  Google Scholar 

  • Kapagi SH, Shao JF, Lwihula GK et al. (1994) Risk factors for HIV infection among women in Dar-es-Salaam, Tanzania. J Acquir Immune Defic Syndr 7: 301–309

    Google Scholar 

  • Katz Z, Lancet M, Skornik Jet al. (1985) Teratogenicity of progestogens given during the first trimester of pregnancy. Obstet Gynecol 65: 775–780

    PubMed  CAS  Google Scholar 

  • Kesserü EV, Aydinlik S, Etchepareborda JJ (1994) Multicentred, phase III clinical trial of norethisterone enanthate 50 mg plus estradiol valerate 5 mg as a monthly injectable contraceptive; final three-year report. Contraception 50: 329–337

    Article  Google Scholar 

  • Koetsawang S (1994) Once-a-month injectable contraceptives: efficacy and reasons for discontinuation. Contraception 49: 387–398

    Article  PubMed  CAS  Google Scholar 

  • Koetsawang S, Nukulkarn P, Fotherby K et al. (1982) Transfer of contraceptive steroids in milk of women using long-acting gestagens. Contraception 25: 321–331

    Article  PubMed  CAS  Google Scholar 

  • La Veccia C (1994) Depot-medroxyprogesterone acetate, other injectable contraceptives, and cervical neoplasia. Contraception 49: 223–230

    Article  Google Scholar 

  • Lan PT, Aedo AR, Landgren BM, Johannisson E, Diczfalusy E (1984) Return of ovulation following a single injection of Depo-Medroxy-Progesterone acetate: a pharmacokinetic and pharmacodynamic study. Contraception 29: 1–18

    Article  PubMed  CAS  Google Scholar 

  • Lei ZW, Wu SC, Garceau RJ et al. (1996) Effect of pretreatment counseling on discontinuation rates in chinese women given depo-medroxyprogesterone acetate for contraception. Contraception 53: 357361

    Google Scholar 

  • Lumbiganon P (1994) Depot-medroxyprogesterone acetate (DMPA) and cancer of the endometrium and ovary. Contraception 49: 203–209

    Article  PubMed  CAS  Google Scholar 

  • Marcus T. et al. (1985) Menstrual function and bone mass in elite women distance runners. Ann Intern Med 102: 158–164

    PubMed  CAS  Google Scholar 

  • Marx PA, Spira AI, Gettie A et al. (1996) Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 2: 1084–1089

    Article  PubMed  CAS  Google Scholar 

  • Mati JKG, Hunter DJ, Maggwa BN et al. (1995) Contraceptive use and the risk of HIV infection in Nairobi, Kenya. Int J Obstet Gynaecol 48: 61–67

    Google Scholar 

  • McDaniel E, Pardthaisong, MA (1973) Depot-medroxyprogesterone acetate as a contraceptive agent: return of fertility after discontinuation of use. Contraception 8: 407–414

    Article  Google Scholar 

  • Mishell DR et al. (1972) Estrogenic activity in women receiving an injectable progestogen for contraception. Am J Obstet Gynecol 113: 372–376

    PubMed  Google Scholar 

  • Mukherjea M, Mukherjee P, Biswas R (1980) Long-term contraception with Depo-Provera: a clinical evaluation. Int J Fertil 25: 122–126

    PubMed  CAS  Google Scholar 

  • Newton JR, D’Arcangues C, Hall PE (1994) ‘Once-a-month’ combined injectable contraceptives. J Ob-stet Gynaecol 14 [Suppl 1]

    Google Scholar 

  • Ortiz A, Hiroi M, Stanczyk FZ, Goebelsmann U, Mishell DR (1977) Serum medoxyprogesterone acetate ( MPA) concentrations and ovarian function following intramuscular injection of Depo-MPA. J Clin Endocrinol Metab 44: 32–38

    Google Scholar 

  • Pardthaisong, T (1984) Return of fertility after use of the injectable contraceptive Depo-Provera: updated data analysis. J Biosoc Sci 16: 23–24

    Article  PubMed  CAS  Google Scholar 

  • Pardthaisong T, Yenchit C, Gray R (1992) The long-term growth and development of children exposed to Depo-provera during pregnancy or lactation. Contraception 45: 313–324

    Article  PubMed  CAS  Google Scholar 

  • Paul C, Skegg DCG, Spears GFS (1989) Depot medroxyprogesterone ( Depo-Provera) and risk of breast cancer. BMJ 299: 759–762

    Google Scholar 

  • Piya-Anant M, Koetsawang S, Patrasupapong N et al. (1998) Effectiveness of Cyclofem in the treatment of DMPA-induced amenorrhea. Contraception (in press)

    Google Scholar 

  • Population Reports (1995) Series K, No. 5, Baltimore, John Hopkins School of Public Health, Population Information Program

    Google Scholar 

  • Product Information (1994) Depo-Provera Contraceptive Injection. MI:Upjohn Company, Kalamazoo Rehle T, Brinkmann U, Siraprapasiri T et al. (1992) Risk factors of HIV-1 infection among female prostitutes in Khon Kaen, Northeast Thailand. Infection 20: 328–331

    Google Scholar 

  • Sang GW, Shao QX, Ge RS et al. (1995) A multicentred phase III comparative clinical trial of mesigyna, cyclofem and injectalbe No.1 given monthly by intramuscular injection to Chinese women. Contraception 51: 167–183

    Article  PubMed  CAS  Google Scholar 

  • Saxena BN, Datey S, Gupta S et al. (1986) ICMR task force on hormonal contraception: return of fertility following discontinuation of an injectable contraceptive–norethisterone Oenanthate (NET EN) 200 mg dose. Contraception 34: 573–582

    Article  Google Scholar 

  • Schwallie PC, Assenzo, Jr. (1973) Contraceptive use-efficacy study utilizing medroxyprogesterone ace-tate administered as an intramuscular injection once every 90 days. Fertil Steril24: 331–339

    Google Scholar 

  • Siegel I (1963) Conception control by long-acting progestogens: Preliminary report. Obstet Gynecol 21: 666–668

    PubMed  CAS  Google Scholar 

  • Siraprapasiri T, Rehle T, Brinkmann UK, Coplan P, Aiemsukawat C, Ungchusak K (1992) Risk factors of HIV-1 infection among female prostitutes in Khon Kaen, Northeast Thailand. Infection. 20: 328–331

    Google Scholar 

  • Skegg DCG, Noonan EA, Paul C et al. (1995) Depot medroxyprogesterone acetate and breast cancer. A pooled analysis of the World Health Organization and New Zealand Studies. JAMA 273: 799–804

    Google Scholar 

  • Snead DB et al. (1992) Reproductive hormones and bone mineral density in women runners. J Appl Physiol 72: 2149–2156

    Article  PubMed  CAS  Google Scholar 

  • Snow R, Garcia S, Kureshy N et al. (1997) Attributes of contraceptive technology: women’s preferences in seven countries. Reprod Health Matters pp 36–48

    Google Scholar 

  • Snow R, Hall P (eds.) (1994) Steroid contraceptives and women’s response. Plenum Press, New York

    Google Scholar 

  • Stevens VC, Griffin PD, Jones WR (1997) Immunocontraceptives: an update. Bio Drugs

    Google Scholar 

  • Taneepanichskul S, Intaraprasert S, Theppisai U et al. (1997) Bone mineral density in long-term depot medroxyprogesterone acetate acceptors. Contraception 56: 1–3

    Article  PubMed  CAS  Google Scholar 

  • The CONRAD Program (1996) Annual Report

    Google Scholar 

  • Thomas DB, Molina R, Cuevas HR et al. (1989) Monthly injectable steroid contraceptives and cervical carcinoma. Am J Epidemiol 130: 237–247

    PubMed  CAS  Google Scholar 

  • Ungchusak K, Rehle T, Thammapornpilap P, Spiegelman D, Brinkmann U, Siraprapasiri T (1996) Determinants of HIV infection among female commercial sex workers in northeastern Thailand: results from a longitudinal study. J Acquir Immune Defic Syndr Hum Retrovirol 12: 500–507

    Article  PubMed  CAS  Google Scholar 

  • UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction. Annual Technical Report 1997

    Google Scholar 

  • UNDP/UNFPA/WHO/World Bank, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-Acting Systemic Agents for Fertility Regulation (1997) Comparative Study of the effects of two once-a-month injectable steroidal contraceptives ( Mesigyna and Cyclofem) on Lipid and Lipoprotein metabolism. Contraception 56: 193–207

    Google Scholar 

  • UNDP/UNFPA/WHO/World Bank, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-Acting Systemic Agents for Fertility Regulation 1998. Comparative Study of the effects of two once-a-month injectable steroidal contraceptives ( Mesigyna and Cyclofem) on Glucose Metabolism and Liver Function. Contraception 57: 71–81.

    Google Scholar 

  • Virutamasen P, Leepipatpaiboon S, Kriengsinyot R et al. (1996) Pharmacodynamic effects of depotmedroxyprogesterone acetate ( DMPA) administered to lactating women on their male infants. Contraception 54: 153–157

    Google Scholar 

  • World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Oral Contraceptives (1984) Effects of hormonal contraceptives on milk volume and infant growth. Contraception 30: 505–522

    Article  Google Scholar 

  • World Health Organization (1986) A multicentred phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: 1. Contraceptive efficacy and side effects. Contraception 34: 223–236

    Article  Google Scholar 

  • World Health Organization, Special programme of research, development and research training in human reproduction. Task Force on long-acting systemic agents for fertility regulation (1987) A multicentred pharmacokinetic, pharmacodynamic study of once-a-month injectable contraceptives. I. Different doses of HRP112 and Depoprovera. Contraception 36: 441–457

    Article  Google Scholar 

  • World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Oral Contraceptives, Effects of hormonal contraceptives on breast milk composition and infant growth (1988a) Studies in Family Planning 19: 361–369

    Article  Google Scholar 

  • World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on Long-acting Systemic Agents for Fertility Regulation (1988b) A multicentred phase III comparative study of two hormonal contraceptive preparations given once-amonth by intra-muscular injection: I. Contraceptive efficacy and side-effects. Contraception 37: 1–20

    Google Scholar 

  • World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives (1988c) Endometrial cancer and combined oral contraceptives. Int J Epidemiol 17: 263–269

    Article  Google Scholar 

  • World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives (199la) Breast cancer and depot-medroxyprogesterone acetate: a multinational study. Lancet 338:833–838

    Google Scholar 

  • World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives (1991b) Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. Int J Cancer 49: 186–190

    Google Scholar 

  • World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-Acting Systemic Agents for Fertility Regulation (1993) A Multicentre Comparative Study of Serum Lipids and Apolipoproteins in Longterm Users of DMPA and a Control Group of IUD Users. 47: 177–191

    Google Scholar 

  • World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction. Task Force for Epidemiological Research on Reproductive Health (1994a) Progestogen-only contraceptives during lactation: I. Infant growth. Contraception 50: 35–53

    Google Scholar 

  • World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction. Task Force for Epidemiological Research on Reproductive Health (1994b) Progestogen-only contraceptives during lactation: II. Infant development. Contraception 50: 55–68

    Google Scholar 

  • World Health Organization, Family and Reproductive Health (1996a) Improving access to quality care in family planning. Medical eligibility criteria for contraceptive use. pp 143

    Google Scholar 

  • World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation (1996b) Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulfate on prolonged bleeding in women using depot-medroxyprogesterone acetate (DMPA) for contraception. Human Reproduction 11 [suppl 21: 1–13

    Google Scholar 

Download references

Authors
  1. Catherine d’Arcangues
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rachel C. Snow
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

d’Arcangues, C., Snow, R.C. (1999). Injectable Contraceptives. In: Fertility Control — Update and Trends. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-86696-8_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-86696-8_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-86698-2

  • Online ISBN: 978-3-642-86696-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation